Simulations Plus Inc
NASDAQ:SLP

Watchlist Manager
Simulations Plus Inc Logo
Simulations Plus Inc
NASDAQ:SLP
Watchlist
Price: 31.32 USD 4.26% Market Closed
Market Cap: 628.6m USD
Have any thoughts about
Simulations Plus Inc?
Write Note

Simulations Plus Inc
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Simulations Plus Inc
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Simulations Plus Inc
NASDAQ:SLP
Cash & Cash Equivalents
$10.3m
CAGR 3-Years
-35%
CAGR 5-Years
-2%
CAGR 10-Years
2%
Veeva Systems Inc
NYSE:VEEV
Cash & Cash Equivalents
$1.2B
CAGR 3-Years
3%
CAGR 5-Years
7%
CAGR 10-Years
24%
Inspire Medical Systems Inc
NYSE:INSP
Cash & Cash Equivalents
$147.5m
CAGR 3-Years
-11%
CAGR 5-Years
25%
CAGR 10-Years
N/A
Doximity Inc
NYSE:DOCS
Cash & Cash Equivalents
$96.8m
CAGR 3-Years
13%
CAGR 5-Years
24%
CAGR 10-Years
N/A
Omnicell Inc
NASDAQ:OMCL
Cash & Cash Equivalents
$570.6m
CAGR 3-Years
6%
CAGR 5-Years
33%
CAGR 10-Years
19%
W
Waystar Holding Corp
NASDAQ:WAY
Cash & Cash Equivalents
$35.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Simulations Plus Inc
Glance View

Market Cap
628m USD
Industry
Health Care

Simulations Plus, Inc. provides modeling and simulation software and consulting services supporting drug discovery, development research and regulatory submissions. The company is headquartered in Lancaster, California and currently employs 135 full-time employees. The company provides prediction of properties of molecules utilizing artificial-intelligence- and machine-learning-based technology. The company also provides consulting services ranging from early drug discovery through preclinical and clinical trial development to regulatory submissions in support of product approval. The company offers 11 software products for pharmaceutical research and development, which includes GastroPlus, DDDPlus, MembranePlus, DILIsym, NAFLDsym, ADMET Predictor, MedChem Designer, MedChem Studio, PKPlus, KIWI and Monolix Suite of products through Lixoft. Its software and consulting services are provided to pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies and to academic and regulatory agencies worldwide for use in the conduct of industry-based research. Cognigen Corporation, DILIsym Services, Inc. and Lixoft are its subsidiaries.

SLP Intrinsic Value
20.55 USD
Overvaluation 34%
Intrinsic Value
Price

See Also

What is Simulations Plus Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
10.3m USD

Based on the financial report for Aug 31, 2024, Simulations Plus Inc's Cash & Cash Equivalents amounts to 10.3m USD.

What is Simulations Plus Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
2%

Over the last year, the Cash & Cash Equivalents growth was -82%. The average annual Cash & Cash Equivalents growth rates for Simulations Plus Inc have been -35% over the past three years , -2% over the past five years , and 2% over the past ten years .

Back to Top